Neueste Versuche

EudraCT Number: 2004-004681-33 Sponsor Protocol Number: D1447C00001 Start Date: 2005-04-15
Sponsor Name: AstraZeneca AB
Full Title: An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600...
Medical condition: Bipolar Depression
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: LT (Completed) LV (Completed) EE (Completed) DE (Completed)
Trial results: View results
EudraCT Number: 2004-005164-25 Sponsor Protocol Number: 04.09 Start Date: 2005-04-14
Sponsor Name: Odense University Hospital
Full Title: Phase II study of thalidomide in combination with temozolomide in metastatic malignant melanoma with brain metastases
Medical condition: Advanced metastic malignant melanoma
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Completed)
Trial results: (No results available)
EudraCT Number: 2005-000859-15 Sponsor Protocol Number: ML 18542 Start Date: 2005-04-14
Sponsor Name: ROCHE
Full Title: Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults.
Medical condition: Front-line treatment of adult ITP
Disease: Version SOC Term Classification Code Term Level
6.1 10021245 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Completed)
Trial results: View results
EudraCT Number: 2004-003929-27 Sponsor Protocol Number: STRADIVARIUS Start Date: 2005-04-14
Sponsor Name: SANOFI-SYNTHELABO
Full Title: Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by IVUS (IntraVascular UltraSo...
Medical condition: Inhibition of coronary atherosclerosis progression in overweight patients with a cluster of risk factors.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IT (Completed) ES (Completed)
Trial results: View results
EudraCT Number: 2004-002560-17 Sponsor Protocol Number: 25543 Start Date: 2005-04-14
Sponsor Name: NV Organon
Full Title: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizop...
Medical condition: Schizophrenia with predominant, persistent negative symptoms
Disease: Version SOC Term Classification Code Term Level
7.1 10039626 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FI (Completed) DK (Prematurely Ended) SE (Completed) DE (Completed) CZ (Completed) GB (Completed) IT (Completed) ES (Completed) HU (Completed)
Trial results: View results
EudraCT Number: 2004-005166-20 Sponsor Protocol Number: 04.10 Start Date: 2005-04-14
Sponsor Name: Odense University Hospital
Full Title: Phase II study of first-line therapy with Thalidomide in combination with Peg-introna and decrescendo IL-2 in patients with metastatic malignant melanoma
Medical condition: Metastatic malignant melanoma
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Completed)
Trial results: (No results available)
EudraCT Number: 2005-000366-39 Sponsor Protocol Number: Astra-003 Start Date: 2005-04-14
Sponsor Name: Inamed Research GmbH & Co. KG
Full Title: Effect of Oxis on the Efficacy of Mucociliary Clearance in Patients with COPD
Medical condition: Chronic obstructive pulmonary disease
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Female
Trial protocol: DE (Completed)
Trial results: (No results available)
EudraCT Number: 2004-004053-26 Sponsor Protocol Number: SEEG 0001 Start Date: 2005-04-14
Sponsor Name: Birthe Pedersen
Full Title: An explorative use open-label, multi-center, randomized trial studying the safety and efficacy of levetiracetam (500 mg/day to 3000 mg/day) and valproate (600 mg/day to 3000 mg/day) as monotherapy ...
Medical condition: Newly diagnosed epilepsy patients are over 65 years. In this age group more cases are symptomatic and it is apparently another disorder than epilepsy in adults. Epilepsy in the elderly is easier to...
Disease: Version SOC Term Classification Code Term Level
Population Age: Elderly Gender: Male, Female
Trial protocol: SE (Prematurely Ended) DK (Completed)
Trial results: (No results available)
EudraCT Number: 2004-002914-12 Sponsor Protocol Number: 0018 Start Date: 2005-04-13
Sponsor Name: Theravance Inc.
Full Title: A phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Televancin Versus Vancomycin for Treatment of Complicated Gram-positive Skin and Skin Structure Infections with a focus on Pa...
Medical condition: Complicated Gram-Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus aureus.
Disease: Version SOC Term Classification Code Term Level
7.0 10040872 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: LT (Completed) GB (Completed) IT (Completed)
Trial results: View results
EudraCT Number: 2005-000313-35 Sponsor Protocol Number: 041210 Start Date: 2005-04-13
Sponsor Name: Aerovance Inc
Full Title: A Phase I/II Study to Investigate the Efficacy and Safety of AER 002 in Cystic Fibrosis Given at 3 mg, 10 mg, and 30 mg Doses in Single then Multiple Ascending Doses and to Determine Efficacy of th...
Medical condition: Cystic Fibrosis
Disease: Version SOC Term Classification Code Term Level
7.1 10011762 LLT
Population Age: Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: (No results available)

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren